Benitec Biopharma

Benitec Biopharma's BB-301, an AAV vector-based gene therapy for OPMD-related dysphagia, showed clinically meaningful improvements in swallowing in two patients treated in a phase 1b/2a trial. Patient 1 had a 35% reduction in SSQ total score and improvements in VFSS TPR, while Patient 2 achieved an 89% improvement in SSQ Total Score and a 92% reduction in low-volume sequential swallows. Both patients were treated with a low dose of BB-301, 1.2x10^13 vg/subject, with no significant adverse events reported.

Benitec Biopharma reports durable improvements in swallowing for two OPMD patients treated with BB-301 gene therapy, with one achieving clinically normal swallowing. The company plans to discuss these interim results in a conference call on October 14.

Benitec Biopharma reports positive interim data from Phase 1b/2a study of BB-301 for OPMD, showing durable, clinically meaningful improvements in swallowing for two subjects treated with low-dose BB-301 at 9 and 6 months post-treatment, respectively.

Subjects 1 and 2 showed durable, clinically meaningful improvements in swallowing post-BB-301 treatment, with Subject 2 achieving a clinically normal swallowing profile. Management plans to discuss interim results in a conference call on October 14.

Subjects 1 and 2 showed durable, clinically meaningful improvements in swallowing post-BB-301 treatment, with Subject 2 achieving a clinically normal swallowing profile. Benitec Biopharma plans to discuss these interim results in a conference call on October 14.

Earli, a Silicon Valley startup, develops a 'synthetic biopsy' platform to detect cancer early by programming cancer cells to reveal themselves and self-destruct. Recently, Accenture Ventures invested strategically, emphasizing early diagnosis's potential to improve outcomes. Earli's technology, combining cell programming with high-sensitivity detection, aims to detect multiple cancer types non-invasively. The collaboration with Accenture leverages data science and AI to refine detection models, enhancing precision and efficacy in cancer detection.